SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001439222-23-000117
Filing Date
2023-08-03
Accepted
2023-08-03 06:38:04
Documents
14
Period of Report
2023-08-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K agio-20230803.htm   iXBRL 8-K 32792
2 EX-99.1 agio-080323xex991earningsr.htm EX-99.1 75385
6 GRAPHIC image_0.jpg GRAPHIC 55469
  Complete submission text file 0001439222-23-000117.txt   319867

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT agio-20230803.xsd EX-101.SCH 1883
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT agio-20230803_lab.xml EX-101.LAB 23834
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT agio-20230803_pre.xml EX-101.PRE 12496
8 EXTRACTED XBRL INSTANCE DOCUMENT agio-20230803_htm.xml XML 2720
Mailing Address 88 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 88 SIDNEY STREET CAMBRIDGE MA 02139 617-649-8600
AGIOS PHARMACEUTICALS, INC. (Filer) CIK: 0001439222 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36014 | Film No.: 231137939
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences